Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IRAS No: 354646 | Other Identifier | Health Research Authority (HRA), United Kingdom | |
| REC reference: 26/LO/0362 | Other Identifier | London - Chelsea Research Ethics Committee |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Imperial College London | OTHER |
Not provided
Not provided
Not provided
Not provided
This study is a single-site feasibility randomised controlled trial evaluating the feasibility and acceptability of electroacupuncture (EA), percutaneous tibial nerve stimulation (PTNS), and sham electroacupuncture in women with refractory overactive bladder (OAB) who have not achieved satisfactory improvement following standard pelvic health physiotherapy.
The primary aim is to determine whether a larger definitive trial is feasible by assessing recruitment, consent, retention, treatment adherence, data completeness, intervention delivery, blinding credibility, safety, and participant acceptability.
Thirty-six participants will be randomly allocated to receive electroacupuncture, PTNS, or sham electroacupuncture over a 12-week treatment period. Outcome assessments will be completed at baseline, 6 weeks, 12 weeks, 6 months, and 12 months.
The findings will inform the design of a future definitive randomised controlled trial and contribute to the evidence base for non-pharmacological treatment options for overactive bladder.
Overactive bladder (OAB) is a common and distressing condition characterised by urinary urgency, frequency, nocturia, and, in some cases, urgency urinary incontinence. OAB can substantially affect quality of life, psychological wellbeing, social participation, and healthcare utilisation. Although first-line management includes behavioural interventions and pelvic floor physiotherapy, a proportion of women continue to experience bothersome symptoms despite these treatments and require additional therapeutic options.
Electroacupuncture (EA) has emerged as a potential treatment for lower urinary tract symptoms and overactive bladder. Previous studies suggest that EA may improve urinary symptoms through neuromodulatory mechanisms; however, the quality, consistency, and applicability of the evidence remain uncertain. Percutaneous tibial nerve stimulation (PTNS) is an established neuromodulation treatment used within clinical practice and is recommended for selected patients with refractory OAB. To date, there is limited evidence directly comparing EA with PTNS, and uncertainty remains regarding the feasibility of conducting a definitive comparative trial.
The purpose of this study is to evaluate the feasibility and acceptability of a three-arm randomised controlled trial comparing electroacupuncture, PTNS, and sham electroacupuncture in women with refractory OAB.
This is a single-centre feasibility randomised controlled trial conducted within a pelvic health physiotherapy service. Thirty-six women with refractory OAB will be randomised in a 1:1:1 ratio to receive:
Participants will receive weekly treatment sessions for 12 weeks and will be followed up at baseline, 6 weeks, 12 weeks, 6 months, and 12 months.
The primary outcomes are feasibility outcomes, including:
Exploratory clinical outcomes include:
The study is not powered to detect treatment effectiveness. Findings will be used to estimate key feasibility parameters and inform the design, conduct, and sample size calculation of a future definitive randomised controlled trial.
The study has received favourable ethical approval from a UK Research Ethics Committee and NHS Research & Development approval. The study is sponsored by Chelsea and Westminster Hospital NHS Foundation Trust and forms part of a PhD programme at Imperial College London.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1: Electroacupuncture (EA) Group Experimental | Experimental | Arm 1: Electroacupuncture (EA) Group Arm Type: Experimental Description: Participants in this group will receive electroacupuncture treatment targeting sacral and lower abdominal acupuncture points traditionally used for overactive bladder (OAB). Sterile, single-use acupuncture needles will be inserted and connected to an electroacupuncture device that delivers a low-frequency electrical current. Duration: 12 weekly sessions over 12 weeks Setting: Delivered by trained pelvic health physiotherapists in an outpatient hospital setting. Intervention: |
|
| Arm 2: Percutaneous Tibial Nerve Stimulation (PTNS) Group | Active Comparator | Arm Type: Active Comparator Description: Participants in this group will receive percutaneous tibial nerve stimulation, a standard treatment for OAB. A fine needle electrode is inserted near the ankle to stimulate the tibial nerve, transmitting signals to the sacral nerve plexus that controls bladder function. Duration: 12 weekly sessions over 12 weeks Setting: Delivered by trained clinicians in an outpatient setting. |
|
| Arm 3: Sham Acupuncture (Control) Group | Sham Comparator | Description: Needles will be placed superficially (2-3 mm depth) at non-acupuncture points located approximately 1-2 cm lateral to the true sacral and abdominal treatment points, avoiding recognised meridian locations. Electrical Stimulation Electrode clips will be attached to needles, and the electroacupuncture device will be activated without delivering electrical output (no current transmission). Visual and auditory cues will be maintained to preserve credibility. This is used as a control to assess the true efficacy of EA compared to placebo. Duration: 12 weekly sessions over 12 weeks Setting: Delivered by trained physiotherapists using standardised placebo protocols. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Name: Electroacupuncture (EA) Type: Device-based acupuncture therapy | Device | Description: Insertion of acupuncture needles at specific points with electrical stimulation (2 Hz) for 30 minutes per session. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Female Lower Urinary Tract Symptoms Measured by ICIQ-FLUTS | Participants will complete the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ-FLUTS) at baseline, 6 weeks, 12 weeks, 6 months, and 12 months. The questionnaire assesses the severity and impact of female lower urinary tract symptoms, including urinary urgency, frequency, nocturia, and urinary incontinence. Changes in questionnaire scores over time will be explored to assess symptom progression and response to treatment. | This questionnaire will be completed at 6 weeks, 12 weeks, 6 months, and 12 months |
| Change in Urinary Symptom-Related Quality of Life Measured by ICIQ-LUTSqol | Participants will complete the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol) questionnaire at baseline, 6 weeks, 12 weeks, 6 months, and 12 months. The questionnaire assesses the impact of lower urinary tract symptoms on quality of life, including physical, social, emotional, and daily activities. Changes in questionnaire scores over time will be explored to assess the impact of treatment on symptom-related quality of life. | This questionnaire will be completed at 6 weeks, 12 weeks, 6 months, and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Participant Satisfaction and Treatment Acceptability | Participants will complete a study-specific Likert-scale questionnaire at 12 weeks to assess satisfaction, perceived benefit, treatment burden, and overall acceptability of the intervention. The questionnaire will explore participants' experiences of treatment, including ease of participation, perceived symptom improvement, and willingness to recommend the intervention to others. Results will be used to evaluate the acceptability and feasibility of the interventions and trial procedures. |
Not provided
Inclusion Criteria:
Participants must meet all of the following criteria:
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded:
Self-identified genders eligible to participate:
Women (Cisgender women)
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elmas Court | Contact | +447538355975 | elmas.court@nhs.net |
| Name | Affiliation | Role |
|---|---|---|
| Leila Janani, PhD | Imperial College London-Advanced Research Fellow / Senior Clinical Trials Statistician Deputy Head of Trial Methodology | Study Chair |
| Deepa Dr Abichandani | Senior Lecturer in Physiotherapy Employability Lead for School of Allied and Community Health London South Bank Universit |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chelsea and Westminster hospital NHS foundation Trust | London | SW10 9NH | United Kingdom |
Undecided: It is not yet known if there will be a plan to make IPD available
Not provided
Not provided
Not provided
Not provided
Not provided
3 arm parallel RCT
Not provided
Not provided
Participants allocated to the electroacupuncture and sham electroacupuncture groups will be blinded to treatment allocation. Due to the nature of the interventions, treatment providers cannot be blinded. Blinding credibility will be assessed at the end of treatment.
|
| Neuromodulation therapy | Device | Type: Neuromodulation therapy Description: Insertion of a needle electrode near the medial malleolus with low-voltage electrical stimulation (20 Hz) applied for 30 minutes per session. |
|
|
| Sham Acupuncture | Device | Type: Placebo Description: Non-invasive, non-penetrating placebo needles placed at the same points as in the EA group, without electrical stimulation, for 30 minutes per session. |
|
| This questionnaire will be completed at 12 weeks (end of treatment) |
| Frequency and Severity of Adverse Events | All adverse events related to EA or PTNS will be recorded and categorised by severity and causality. Monitoring will follow ICH Good Clinical Practice (E6[R2]) standards to ensure participant safety. | From beginning of trial to 12 months after the trial |
| Treatment Compliance and Attendance Rates | Participant adherence will be tracked through a treatment log. Missed sessions and reasons for non-attendance will be recorded to assess treatment feasibility and refine delivery strategies for future implementation. | From randomisation to 12 weeks after randomisation |
| Study Chair |
| Mark Pro. Johnson | Senior Lecturer, Consultant in Obstetrics and Obstetric Medicine Charing Cross Hospital. And Chelsea and Westminster NHS Trust Imperial College London Clinical Chair in Obstetrics Department of Metabolism, Digestion an | Study Chair |
| Rufus Mr. Cartwright | Uro-gynaecologist consultant and Honorary Clinical Senior Lecturer institute of Reproductive and Developmental Biology, Hammersmith Campus and Celsea and Westminster NHS Trust Gynaecology and Departm | Study Director |
| Elmas X Court | Chelsea and Westminster Hospital and Imperial College London | Principal Investigator |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D053158 | Nocturia |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004561 | Transcutaneous Electric Nerve Stimulation |
| ID | Term |
|---|---|
| D004599 | Electric Stimulation Therapy |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D012046 | Rehabilitation |
| D000698 | Analgesia |
| D000760 | Anesthesia and Analgesia |
Not provided
Not provided